Role of aneuploid circulating tumor cells and CD31 ⁺ circulating tumor endothelial cells in predicting and monitoring anti‐angiogenic therapy efficacy in advanced NSCLC

Role of aneuploid circulating tumor cells and CD31 ⁺ circulating tumor endothelial cells in predicting and monitoring anti‐angiogenic therapy efficacy in advanced NSCLC is a paper indexed in ScholarIQ from OpenAlex.

How many citations does Role of aneuploid circulating tumor cells and CD31 ⁺ circulating tumor endothelial cells in predicting and monitoring anti‐angiogenic therapy efficacy in advanced NSCLC have?

Role of aneuploid circulating tumor cells and CD31 ⁺ circulating tumor endothelial cells in predicting and monitoring anti‐angiogenic therapy efficacy in advanced NSCLC has 34 citations in the OpenAlex counts ScholarIQ stores.

When was Role of aneuploid circulating tumor cells and CD31 ⁺ circulating tumor endothelial cells in predicting and monitoring anti‐angiogenic therapy efficacy in advanced NSCLC published?

Role of aneuploid circulating tumor cells and CD31 ⁺ circulating tumor endothelial cells in predicting and monitoring anti‐angiogenic therapy efficacy in advanced NSCLC has 2021 year in the ScholarIQ index.

What is the open-access status of Role of aneuploid circulating tumor cells and CD31 ⁺ circulating tumor endothelial cells in predicting and monitoring anti‐angiogenic therapy efficacy in advanced NSCLC?

Role of aneuploid circulating tumor cells and CD31 ⁺ circulating tumor endothelial cells in predicting and monitoring anti‐angiogenic therapy efficacy in advanced NSCLC has gold oa status in the ScholarIQ index.

What is the DOI of Role of aneuploid circulating tumor cells and CD31 ⁺ circulating tumor endothelial cells in predicting and monitoring anti‐angiogenic therapy efficacy in advanced NSCLC?

The DOI for Role of aneuploid circulating tumor cells and CD31 ⁺ circulating tumor endothelial cells in predicting and monitoring anti‐angiogenic therapy efficacy in advanced NSCLC is on the source record.

What is the PMID of Role of aneuploid circulating tumor cells and CD31 ⁺ circulating tumor endothelial cells in predicting and monitoring anti‐angiogenic therapy efficacy in advanced NSCLC?

The PMID for Role of aneuploid circulating tumor cells and CD31 ⁺ circulating tumor endothelial cells in predicting and monitoring anti‐angiogenic therapy efficacy in advanced NSCLC is on the source record.

What is the OpenAlex record for Role of aneuploid circulating tumor cells and CD31 ⁺ circulating tumor endothelial cells in predicting and monitoring anti‐angiogenic therapy efficacy in advanced NSCLC?

The OpenAlex for Role of aneuploid circulating tumor cells and CD31 ⁺ circulating tumor endothelial cells in predicting and monitoring anti‐angiogenic therapy efficacy in advanced NSCLC is on the source record.